Synovate Adds New Therapy Monitor

Synovate Healthcare has added inflammatory bowel disease(IBD)to its range of Therapy Monitors for the pharmaceutical industry. The Monitors track how certain diseases are treated, managed and perceived over time, based on the experiences and perceptions of a panel of specialist physicians.

IBD, which includes ulcerative colitis and Crohn's disease, is of particular interest to the pharmaceutical industry, due to an increasing number of treatment options. The market is likely to change noticeably in the next few years with more than 20 new products in the pipeline. Synovate will receive regular reports about treatments and the nature of the market from a representative panel of doctors across the US and Europe.

The IBD Monitor is the latest in Synovate's portfolio of auto-immune diseases, adding to existing HIV, multiple sclerosis, and rheumatoid arthritis monitors. A global monitor for psoriasis is due to launch soon.

Lucy Ireland, Manager of the IBD Monitor commented: 'We now have the opportunity to expand our expertise in these two key new auto-immune disorders, allowing for in-depth analysis of these diseases as well as a view of brand performance across the auto-immune area.'

The company is online at www.synovate.com/healthcare

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• All news